ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1655

Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis

Kimberly Showalter1, Cynthia Magro 2, Dana Orange 3, Yaxia Zhang 4, Phaedra Agius 5, Jackie Finik 6, Robert Spiera 1 and Jessica Gordon 1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, 3Rockefeller University, New York, 4Hospital for Special Surgery, New York, 5New York Genome Center, New York City, 6Hospital for Special Surgery, New York, NY, New York, NY

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Autoimmune Skin Disease and Dermatopathology, Outcome measures, Systemic sclerosis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system to evaluate histologic change. The purpose of this study is to determine (1) the reliability of our histology scores and (2) if histologic features correlate with clinical findings.

Methods: Skin biopsies were assessed from patients enrolled in Nilotinib (n=7) and Belimumab (n=18) trials. Our skin histology scoring approach, developed with dermatopatholgist (CM) consultation, includes skin thickness (epidermis to subcutis), follicle count, and semi-quantitative (0-3) assessment of infiltrate, collagen density, alpha-smooth muscle actin (aSMA) and CD34 staining intensity, and global histologic severity. Blinded to prior scores, a dermatopathogist (CM) and second pathologist (YZ), oriented to our approach, analyzed a sub-sample of biopsies. Intraclass correlation coefficients (ICC) were calculated for inter- and intra-rater reliability. Spearman correlations were used to correlate histology scores (baseline, 52-weeks post-treatment, and overall) and clinical variables (local and total modified Rodnan skin score (MRSS), erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), 36-item Short Form Health Survey (SF-36), and physician global assessment (PGA)).

Results: 56 biopsies were analyzed from 26 diffuse SSc patients (median (IQR) disease duration 0.8 (0.54) years). Most were female (77%), Caucasian (73%), and RNA polymerase III positive (58%). Median (IQR) baseline MRSS was 25 (9). Reliability was excellent (ICC≥0.90) for follicle count and intra-rater CD34; good (0.75< ICC >0.90) for thickness, inter-rater CD34, intra-rater collagen density, and intra-rater global score; and moderate (0.5< ICC >0.75) for infiltrate, intra-rater collagen density, aSMA, and inter-rater global score.

Histologic scores correlated moderately with MRSS, ESR, CRP, and SF-36 (Table 1). Post-treatment local MRSS correlated with thickness (r=0.674, p< 0.001), collagen density (r=0.497, p=0.04), global histologic severity (r=0.467, p=0.02), follicle count (r=-0.550, p=0.01), and CD34 stain intensity (r=-0.653, p=0.001). However, local MRSS did not correlate with infiltrate score or PGA and weakly correlated with aSMA stain intensity (r=0.337, p=0.01). In stratified analysis, collagen density correlated with local MRSS in patients with low (< 1) but not high (≥1) infiltrate score (r=0.578, p< 0.001 vs. r=0.253, p=0.256). Total MRSS correlated with collagen density (r=0.425, p=0.001) and CD34 stain intensity (r=-0.460, p< 0.001). Total MRSS and thickness correlated positively in patients with low infiltrate (r=0.326, p=0.05) but negatively in patients with high infiltrate (r=-0.456, p=0.03).

Conclusion: Our scores demonstrate moderate to excellent reliability, thus have potential to be used across centers. Histologic features correlate with MRSS, inflammatory markers, and patient reported outcomes. However, infiltrate does not correlate with MRSS and confounds the correlation of MRSS with collagen density and thickness. This supports further study of skin histology as an SSc outcome measure.


Table1_Histology


Disclosure: K. Showalter, None; C. Magro, None; D. Orange, None; Y. Zhang, None; P. Agius, None; J. Finik, None; R. Spiera, BMS, 2, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 2, ChemoCentryx, 2, 5, Chemocentryx, 2, Corbus, 2, CSL Behring, 5, Cytori, 2, Formation Biologics, 2, Genentech, Inc., 2, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, GSK, 2, 5, Hoffman-La Roche Ltd, 2, Janssen, 5, Mitsubishi, 5, Roche, 2, Roche Genetech, 2, 5, Roche/Genetech, 2, 5, Roche-Genentech, 2, 5, Roche-Genetech, 2, 5, Sanofi, 5, Sanofi-Aventis, 5; J. Gordon, Cumberland, 2, Corbus, 2.

To cite this abstract in AMA style:

Showalter K, Magro C, Orange D, Zhang Y, Agius P, Finik J, Spiera R, Gordon J. Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/histologic-features-correlate-with-the-modified-rodnan-skin-score-serum-inflammatory-markers-and-patient-reported-outcomes-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histologic-features-correlate-with-the-modified-rodnan-skin-score-serum-inflammatory-markers-and-patient-reported-outcomes-in-patients-with-early-diffuse-cutaneous-systemic-sclerosis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology